



## Quantum-Si Launches Platinum® Pro: The End-to-End Solution for Deeper Insights in Proteomics

January 13, 2025

BRANFORD, Conn.--(BUSINESS WIRE)--Jan. 13, 2025-- [Quantum-Si Incorporated](#) (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces the launch of Platinum® Pro, its latest benchtop sequencer that sets a new standard in protein analysis. Designed to redefine efficiency and versatility in proteomics research, Platinum Pro is now available for ordering.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20250113845303/en/>



The new Platinum® Pro system from Quantum-Si is now available to order. (Photo: Business Wire)

Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins in a simple, integrated workflow. Its design prioritizes accessibility, transforming complex protein sequencing

into a seamless process for every lab, everywhere.

Platinum Pro is Quantum-Si's newest Next-Generation Protein Sequencer™ built from the foundation of innovation established by the original Platinum. It introduces advanced features specifically tailored to address the evolving needs of researchers and biopharmaceutical customers. Its key innovations include:

- **Streamlined User Experience:** Platinum Pro features an enlarged touchscreen with an elegant user interface that guides the user through the course of a run enabling diverse applications from proteoform analysis to protein barcoding and beyond.
- **Flexible Data Analysis:** Users can perform data analysis locally or leverage cloud-based solutions, providing versatility to suit diverse research environments.
- **Pro Mode:** This feature empowers custom application development, offered through a Technology Access Program, making Platinum Pro a platform for biopharmaceutical innovation and co-development relationships.

"Platinum Pro represents a significant step forward in our mission to democratize access to proteomics," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "By combining ease of use with customizable features, we're equipping researchers with the tools they need to unlock new frontiers in protein analysis."

"The launch of Platinum Pro marks a major milestone for Quantum-Si as we continue to push the boundaries of proteomics," said Todd Bennett, Chief Commercial Officer of Quantum-Si. "We are also thrilled to announce that our new partnership with Avantor is now in effect, which extends our reach, making Platinum Pro now available for ordering in the U.S. and Canada through their trusted network."

Platinum Pro is the latest demonstration of Quantum-Si's commitment to delivering cutting-edge solutions for next-generation protein sequencing. With its robust capabilities, the system is expected to drive new opportunities for breakthrough discoveries. Now available to order, Platinum Pro will begin shipping in the first quarter. To place an order or learn more about Platinum Pro, visit: [The Protein Sequencing Company™](#) [Quantum-Si](#).

### About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's Platinum® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at [quantum-si.com](http://quantum-si.com) or follow us on [LinkedIn](#) or [X](#).

### Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company's ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized Platinum® protein sequencing instrument and kits and the Company's other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once

commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250113845303/en/): <https://www.businesswire.com/news/home/20250113845303/en/>

**Investor**

Jeff Keyes  
Chief Financial Officer  
[ir@quantum-si.com](mailto:ir@quantum-si.com)

**Media**

Katherine Atkinson  
SVP, Commercial Marketing  
[media@quantum-si.com](mailto:media@quantum-si.com)

Source: Quantum-Si Incorporated